<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053647</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0021</org_study_id>
    <nct_id>NCT04053647</nct_id>
  </id_info>
  <brief_title>Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy (Qol-Hypopara)</brief_title>
  <official_title>Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier le Mans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pitié-Salpêtrière Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persistent hypoparathyroidism is an underestimate but major complication of total&#xD;
      thyroidectomy. The hypothesis of the investigators is that the mental health is impaired in&#xD;
      hypoparathyroid patients compared with thyroidectomized patients without hypoparathyroidism.&#xD;
      The investigators evaluated the quality of life using the SF-36 survey in comparison with a&#xD;
      control population of patients thyroidectomized but free from this complication. The voice&#xD;
      quality, the cardiovascular risk, the kidney function and the incidence of urinary lithiasis&#xD;
      were also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent hypoparathyroidism is an underestimate but major complication of total&#xD;
      thyroidectomy. In this retrospective, observational, multicentre study, the investigators&#xD;
      evaluated the quality of life using the SF-36 survey in comparison with a control population&#xD;
      of patients thyroidectomized but free from this complication. Patients in six centers in&#xD;
      France (Angers, Le Mans, Limoges, Nancy, Nantes, la Pitié-Salpétrière) and in the association&#xD;
      &quot;Hypoparathyroïdisme France&quot; were contacted by mail. The primary endpoint was the mental&#xD;
      health. The physic and global quality of life scores were assessed as secondary endpoints.&#xD;
      Medical and VHI surveys were also send to the patients. The voice quality, the cardiovascular&#xD;
      risk, the kidney function and the incidence of urinary lithiasis were also evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Actual">June 24, 2020</completion_date>
  <primary_completion_date type="Actual">June 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mental health</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Items from mental quality of life score defined by the SF36 (Short Form 36) survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical quality score</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Items from the SF36 (Short Form 36) survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global quality of life score</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Items from the SF36 (Short Form 36) survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voice quality</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Items from the VHI (Voice Handicap Index) survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function quality</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Serum creatinine and clearance dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of urinary lithiasis</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Serum creatinine and clearance dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of cardiovascular complications</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Defined as ischemic cardiopathy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">143</enrollment>
  <condition>Hypoparathyroidism</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Hypoparathyroid patients</arm_group_label>
    <description>Patients with persistent hypoparathyroidism after total thyroidectomy, defined as serum PTH inferior to 15 pg/mL 6 months after surgery and the need of vitamin-calcic supplementation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients, without hypoparathyroidism</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional study</intervention_name>
    <description>Non-interventional study</description>
    <arm_group_label>Control patients, without hypoparathyroidism</arm_group_label>
    <arm_group_label>Hypoparathyroid patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is that of hypoparathyroid patients of the Hypoparathyroidism France&#xD;
        combination who have undergone total thyroidectomy and who have agreed to participate in&#xD;
        the study.&#xD;
&#xD;
        Patients with permanent hypoparathyroidism who were included in the ThyrQol study and in&#xD;
        the FOTHYR study will also be solicited. Endocrinologists at the University Hospital of&#xD;
        Nantes also have patients with permanent hypoparathyroidism in their patients.&#xD;
&#xD;
        The control population consists of patients who had a total thyroidectomy and were included&#xD;
        in the ThyrQol study between 2014 and 2018, without sequelary hypoparathyroidism.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients operated of total thyroidectomy&#xD;
&#xD;
          -  Patients suffering from persistent hypoparathyroidism defined as serum PTH inferior to&#xD;
             15 pg/mL 6 months after the surgery, requiring vitamin-calcic supplementation.&#xD;
&#xD;
          -  Age superior to 18&#xD;
&#xD;
          -  Answering the survey&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy at the time of the study&#xD;
&#xD;
          -  Age inferior to 18 or adult under guardianship&#xD;
&#xD;
          -  Patients with vitamino-calcic supplementation without serum PTH measurement&#xD;
&#xD;
          -  Cause of hypoparathyroidism other than post-operatory.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

